Skip to Main Content

Paper Details

Development of a Covalent Inhibitor of c-Jun N-Terminal Protein Kinase (JNK) 2/3 with Selectivity over JNK1.
J Med Chem
4
2023
ATP, Cys116, JNK1, JNK2, JNK3, JNKs, MAPK, N, YL5084, c-Jun N-Terminal Protein Kinase (JNK) 2/3, c-Jun N-terminal kinases, mitogen-activated protein kinase, multiple myeloma cells, myeloma, myeloma cells
Author NameAffiliation
Jianwei CheDana-Farber Cancer Institute, Harvard Medical School
Jianwei CheHarvard Medical School
Kenneth C AndersonDana-Farber Cancer Institute
Kenneth C AndersonThe LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Dana-Farber Cancer Institute
Kenneth C AndersonDana-Farber Cancer Institute
Kenneth C AndersonThe LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Dana-Farber Cancer Institute
Kenneth D WestoverThe University of Texas Southwestern Medical Center at Dallas
Nathanael S Grayand Stanford Cancer Institute, Stanford School of Medicine, Stanford University
Nathanael S Grayand Stanford Cancer Institute, Stanford School of Medicine, Stanford University
  • 1 - 9

Datasets

Release 1.2